Health Care

NewAmsterdam Pharma insider buys 125,000 shares, boosting CSO stake and hinting at upcoming clinical milestones that could lift the stock.

CEO Ryan Fukushima’s recent 14,286‑share sale at $70 signals liquidity needs or confidence shifts – how will Tempus AI’s AI‑diagnostics growth hold the stock?

Dexcom insider sales: Michael Brown’s routine stock trades reveal no market shock, while the company’s CGM pipeline and global expansion keep growth on track.

Werner Robert F.’s 1,598‑share sell‑to‑cover at $151.42 shows Twist Bioscience’s routine insider tax strategy, not a warning, amid strong growth and investor confidence.

Greenland Mines insider buying: CFO Jeff LeBlanc adds 14,000 shares at $9.72, backing a $2B rare‑earth project and 120% IRR—an undervalued play for long‑term investors.

Insider buying at Sensus Healthcare signals confidence in its FDA‑cleared radiation‑therapy devices and promising oncology pipeline, hinting at future upside.

CEO Troy Edward’s recent Kura Oncology share buy shows strong confidence and aligns management’s interests, hinting at a bullish future.

OptimizeRx’s RSU grant to Chief Legal Officer Odence‑Ford Marion signals long‑term confidence—watch vesting dates and milestones for impact on share supply and investor sentiment.

J.H. Whitney’s $116 M sale of 10M Aveanna shares sparks investor interest: market up 7.9%, potential dilution from a 15‑M offering, and strong clinical initiatives.

Hinge Health CFO’s 11,563‑share sale shows routine insider portfolio rebalance, not a red flag. The company’s robust growth and AI platform keep investor confidence high.